Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches

References

• A V. Sur la resorption du pusuaet sur l'alteration du sang dans les maladies clinique de persection nenemant. Premier observation. Rev Med. 1827;2:216.
   Google Scholar
• R V. Weisses Blut und Milztumoren. I Med Z. 1846;5:157.
   Google Scholar
• Rubin AD, Schultz E. Surface immunoglobulins on lymphocytes in leukemia. N Engl J Med. 1972;287:989–990.
   PubMed Web of Science ®Google Scholar
• Fialkow PJ, Najfeld V, Reddy AL, et al. Chronic lymphocytic leukaemia: clonal origin in a committed B-lymphocyte progenitor. Lancet. 1978;2:444–446.
   PubMed Web of Science ®Google Scholar
• Salsano F, Froland SS, Natvig JB, et al. Same idiotype of B-lymphocyte membrane IgD and IgM. Formal evidence for monoclonality of chronic lymphocytic leukemia cells. Scand J Immunol. 1974;3:841–846.
   PubMed Web of Science ®Google Scholar
• Fu SM, Winchester RJ, Feizi T, et al. Idiotypic specificity of surface immunoglobulin and the maturation of leukemic bone-marrow-derived lymphocytes. Proc Natl Acad Sci USA. 1974;71:4487–4490.
   PubMed Web of Science ®Google Scholar
• Schroer KR, Briles DE, Van Boxel JA, et al. Idiotypic uniformity of cell surface immunoglobulin in chronic lymphocytic leukeima. Evidence for monoclonal proliferation. J Exp Med. 1974;140:1416–1420.
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA: Cancer J Clin. 2007;57:43–66.
   PubMed Web of Science ®Google Scholar
• Torre LA, Siegel RL, Ward EM, et al. Global cancer incidence and mortality rates and trends–an update. Cancer Epidemiol. Biomarkers Prev.: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2016;25:16–27.
   Google Scholar
• Mortality GBD, Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388:1459–1544.
   PubMed Web of Science ®Google Scholar
• Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol. 2002;118:1071–1077.
   PubMed Web of Science ®Google Scholar
• Dores GM, Anderson WF, Curtis RE, et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: overview of the descriptive epidemiology. Br J Haematol. 2007;139:809–819.
   PubMed Web of Science ®Google Scholar
• Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma. 2006;47:1477–1480.
   PubMed Web of Science ®Google Scholar
• Cerhan JR, Vachon CM, Habermann TM, et al. Hormone replacement therapy and risk of non-Hodgkin lymphoma and chronic lymphocytic leukemia. Cancer Epidemiol. Biomarkers Prev.: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. 2002;11:1466–1471.
   Google Scholar
• Tamura K, Sawada H, Izumi Y, et al. Chronic lymphocytic leukemia (CLL) is rare, but the proportion of T-CLL is high in Japan. Eur J Haematol. 2001;67:152–157.
   PubMed Web of Science ®Google Scholar
• Yuille MR, Matutes E, Marossy A, et al. Familial chronic lymphocytic leukaemia: a survey and review of published studies. Br J Haematol. 2000;109:794–799.
   PubMed Web of Science ®Google Scholar
• Scarfo L, Ghia P. What does it mean I have a monoclonal B-cell lymphocytosis?: recent insights and new challenges. Semin Oncol. 2016;43:201–208.
   PubMed Web of Science ®Google Scholar
• Scarfo L, Ferreri AJ, Ghia P. Chronic lymphocytic leukaemia. Crit Rev Oncol/Hematol. 2016;104:169–182.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Bennett FL, O'Connor SJ, et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359:575–583.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood. 2002;100:2289–2290.
   PubMed Web of Science ®Google Scholar
• Nieto WG, Almeida J, Romero A, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood. 2009;114:33–37.
   PubMed Web of Science ®Google Scholar
• Marti G, Abbasi F, Raveche E, et al. Overview of monoclonal B-cell lymphocytosis. Br J Haematol. 2007;139:701–708.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Zelenetz AD, Gordon LI, et al. NCCN Guidelines Insights: chronic lymphocytic leukemia/small lymphocytic leukemia, version 1.2017. J Natl Compr Canc Netw. 2017;15:293–311.
   PubMed Web of Science ®Google Scholar
• Kravic-Stevovic T, Bogdanovic A, Boskovic D, et al. Ribosome-lamella complexes in the peripheral blood of patients with chronic lymphocytic leukemia are associated with serological immune deficiency. Ultrastruct Pathol. 2010;34:31–34.
   PubMed Web of Science ®Google Scholar
• Lee S, Graham LM, Chan G, et al. A diagnostic mystery solved by electron microscopy: a case of an "atypical" lymphoproliferative disorder. Ultrastruct Pathol. 2012;36:362–365.
   PubMed Web of Science ®Google Scholar
• Nagy-Simon T, Tatar AS, Craciun AM, et al. Antibody conjugated, raman tagged hollow gold-silver nanospheres for specific targeting and multimodal Dark-Field/SERS/Two Photon-FLIM imaging of CD19(+) B Lymphoblasts. ACS Appl Mater Interfaces. 2017;9:21155–21168.
   PubMed Web of Science ®Google Scholar
• Thakral B, Konoplev S. "Soccer ball" cells to "donut" cells: an unusual case of Richter syndrome. Blood. 2017;130:2358.
   PubMed Web of Science ®Google Scholar
• Quesada AE, Konoplev S. Classical Hodgkin lymphoma arising in a patient with chronic lymphocytic leukemia (Richter syndrome). Blood. 2017;130:2151.
   PubMed Web of Science ®Google Scholar
• Jamroziak K, Tadmor T, Robak T, et al. Richter syndrome in chronic lymphocytic leukemia: updates on biology, clinical features and therapy. Leuk Lymphoma. 2015;56:1949–1958.
   PubMed Web of Science ®Google Scholar
• Baliakas P, Kanellis G, Stavroyianni N, et al. The role of bone marrow biopsy examination at diagnosis of chronic lymphocytic leukemia: a reappraisal. Leuk Lymphoma. 2013;54:2377–2384.
   PubMed Web of Science ®Google Scholar
• Sah SP, Matutes E, Wotherspoon AC, et al. A comparison of flow cytometry, bone marrow biopsy, and bone marrow aspirates in the detection of lymphoid infiltration in B cell disorders. J Clin Pathol. 2003;56:129–132.
   PubMed Web of Science ®Google Scholar
• Dezorella N, Kay S, Baron S, et al. Measurement of lymphocyte aggregation by flow cytometry-physiological implications in chronic lymphocytic leukemia. Cytometry. 2016;90:257–266.
   PubMedGoogle Scholar
• Ozet M. Immunophenotyping of chronic lymphocytic leukemia. Clin Lab. 2017;63:1621–1626.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Fazi C, Agathangelidis A, et al. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study. Leukemia. 2016;30:929–936.
   PubMed Web of Science ®Google Scholar
• Tees MT, Flinn IW. Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease. Expert Rev Hematol. 2017;10:137–146.
   PubMed Web of Science ®Google Scholar
• Craig FE. The utility of peripheral blood smear review for identifying specimens for flow cytometric immunophenotyping. Int J Lab Hematol. 2017;39:41–46.
   PubMed Web of Science ®Google Scholar
• Sandes AF, de Lourdes Chauffaille M, Oliveira CR, et al. CD200 has an important role in the differential diagnosis of mature B-cell neoplasms by multiparameter flow cytometry. Cytometry B Clin Cytom. 2014;86:98–105.
   PubMed Web of Science ®Google Scholar
• Kohnke T, Wittmann VK, Bucklein VL, et al. Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200. Br J Haematol. 2017;179:480–487.
   PubMed Web of Science ®Google Scholar
• Palumbo GA, Parrinello N, Fargione G, et al. CD200 expression may help in differential diagnosis between mantle cell lymphoma and B-cell chronic lymphocytic leukemia. Leuk Res. 2009;33:1212–1216.
   PubMed Web of Science ®Google Scholar
• Challagundla P, Medeiros LJ, Kanagal-Shamanna R, et al. Differential expression of CD200 in B-cell neoplasms by flow cytometry can assist in diagnosis, subclassification, and bone marrow staging. Am J Clin Pathol. 2014;142:837–844.
   PubMed Web of Science ®Google Scholar
• Rahman K, Kumar P, Gupta R, et al. Role of CD200 in differential diagnosis of mature B-cell neoplasm. Int J Lab Hematol. 2017;39:384–391.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kreuzer KA, Soosapilla A, et al. Reproducible diagnosis of Chronic Lymphocytic Leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) harmonisation project. Cytometry Part B, Clinical Cytometry. 2018;94:121–128.
   PubMed Web of Science ®Google Scholar
• Baskar S, Kwong KY, Hofer T, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res: Off J Am Assoc Cancer Res. 2008;14:396–404.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–1916.
   PubMed Web of Science ®Google Scholar
• Put N, Konings P, Rack K, et al. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosom Cancer. 2009;48:843–853.
   PubMed Web of Science ®Google Scholar
• Vargova K, Pesta M, Obrtlikova P, et al. MiR-155/miR-150 network regulates progression through the disease phases of chronic lymphocytic leukemia. Blood Cancer J. 2017;7:e585.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gascon YMI, Hernandez-Sanchez M, Rodriguez-Vicente AE, et al. Characterizing patients with multiple chromosomal aberrations detected by FISH in chronic lymphocytic leukemia. Leuk Lymphoma. 2018;59:633–642.
   PubMed Web of Science ®Google Scholar
• Murphy EJ, Neuberg DS, Rassenti LZ, et al. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. Leukemia. 2017;31:1348–1354.
   PubMed Web of Science ®Google Scholar
• Kim JA, Hwang B, Park SN, et al. Genomic profile of chronic lymphocytic leukemia in Korea identified by targeted sequencing. PLoS One. 2016;11:e0167641.
   PubMed Web of Science ®Google Scholar
• Nguyen-Khac F, Borie C, Callet-Bauchu E, et al. Cytogenetics in the management of chronic lymphocytic leukemia: an update by the Groupe francophone de cytogenetique hematologique (GFCH). Ann Biol Clin. 2016;74:561–567.
   PubMed Web of Science ®Google Scholar
• Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371:1017–1029.
   PubMed Web of Science ®Google Scholar
• Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2002;99:15524–15529.
   PubMed Web of Science ®Google Scholar
• Sava GP, Speedy HE, Di Bernardo MC, et al. Common variation at 12q24.13 (OAS3) influences chronic lymphocytic leukemia risk. Leukemia. 2015;29:748–751.
   PubMed Web of Science ®Google Scholar
• Hui H, Fuller KA, Chuah H, et al. Imaging flow cytometry to assess chromosomal abnormalities in chronic lymphocytic leukaemia. Methods. 2018;134–135:32–40.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gascon YMI, Hernandez-Sanchez M, Rodriguez-Vicente AE, et al. A high proportion of cells carrying trisomy 12 is associated with a worse outcome in patients with chronic lymphocytic leukemia. Hematol Oncol. 2016;34:84–92.
   PubMed Web of Science ®Google Scholar
• Skowronska A, Austen B, Powell JE, et al. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele. Haematologica. 2012;97:142–146.
   PubMed Web of Science ®Google Scholar
• Marasca R, Maffei R, Martinelli S, et al. Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. Hematol Oncol. 2013;31:88–95.
   PubMed Web of Science ®Google Scholar
• Dohner H, Stilgenbauer S, James MR, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. Blood. 1997;89:2516–2522.
   PubMed Web of Science ®Google Scholar
• Austen B, Skowronska A, Baker C, et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol. 2007;25:5448–5457.
   PubMed Web of Science ®Google Scholar
• Slager SL, Rabe KG, Achenbach SJ, et al. Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL. Blood. 2011;117:1911–1916.
   PubMed Web of Science ®Google Scholar
• Wang DM, Miao KR, Fan L, et al. Intermediate prognosis of 6q deletion in chronic lymphocytic leukemia. Leuk Lymphoma. 2011;52:230–237.
   PubMed Web of Science ®Google Scholar
• Vladareanu AM, Ciufu C, Neagu AM, et al. The impact of hepatitis viruses on chronic lymphoproliferative disorders – preliminary results. J Med Life. 2010;3:320–329.
   PubMedGoogle Scholar
• Vasile D, Vladareanu AM, Bumbea H. Peripheral T and NK cell non-hodgkin lymphoma a challenge for diagnosis. Maedica (Buchar). 2014;9:104–108.
   PubMedGoogle Scholar
• Chapiro E, Lesty C, Gabillaud C, et al. "Double-hit" chronic lymphocytic leukemia: an aggressive subgroup with 17p deletion and 8q24 gain. Am J Hematol. 2018;93:375–382.
   PubMed Web of Science ®Google Scholar
• Barrientos JC. Sequencing of chronic lymphocytic leukemia therapies. Hematol Am Soc Hematol Educ Program. 2016;2016:128–136.
   PubMedGoogle Scholar
• Rossi D, Terzi-di-Bergamo L, De Paoli L, et al. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. Blood. 2015;126:1921–1924.
   PubMed Web of Science ®Google Scholar
• Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206.
   PubMed Web of Science ®Google Scholar
• Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750–1757.
   PubMed Web of Science ®Google Scholar
• Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–4088.
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
   PubMed Web of Science ®Google Scholar
• Hallek M. Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017;92:946–965.
   PubMed Web of Science ®Google Scholar
• Innocenti I, Autore F, Pasquale R, et al. Treatment approach for elderly and unfit patients with chronic lymphocytic leukemia. Expert Rev Hematol. 2017;10:1069–1076.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Zaritskey A, Egyed M, et al. Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2017;4:e534–e543.
   PubMed Web of Science ®Google Scholar
• Wilkes GM. Drug essentials. An alkylating agent for CLL and NHL. Oncology (Williston Park, NY). 2009;23:55–56.
   PubMedGoogle Scholar
• Knauf W. Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Rev Anticancer Ther. 2009;9:165–174.
   PubMed Web of Science ®Google Scholar
• Mauro FR, Carella AM, Molica S, et al. Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leuk Lymphoma. 2017;58:1640–1647.
   PubMed Web of Science ®Google Scholar
• Howard DR, Munir T, McParland L, et al. Clinical effectiveness and cost-effectiveness results from the randomised, Phase IIB trial in previously untreated patients with chronic lymphocytic leukaemia to compare fludarabine, cyclophosphamide and rituximab with fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab: the Attenuated dose Rituximab with ChemoTherapy In Chronic lymphocytic leukaemia (ARCTIC) trial. Health Technol Assess. 2017;21:1–374.
   Web of Science ®Google Scholar
• Wendtner CM, Gregor M. Current perspectives on the role of chemotherapy in chronic lymphocytic leukemia. Leuk Lymphoma 2018;59:300–310.
   PubMed Web of Science ®Google Scholar
• Voorhies BN, Stephens DM. What is optimal front-line therapy for chronic lymphocytic leukemia in 2017? Curr Treat Options Oncol. 2017;18:12.
   PubMed Web of Science ®Google Scholar
• Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525–530.
   PubMed Web of Science ®Google Scholar
• Al-Sawaf O, Fischer K, Herling CD, et al. Alemtuzumab consolidation in chronic lymphocytic leukaemia: a phase I/II multicentre trial. Eur J Haematol. 2017;98:254–262.
   PubMed Web of Science ®Google Scholar
• Schweighofer CD, Ritgen M, Eichhorst BF, et al. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG). Br J Haematol. 2009;144:95–98.
   PubMed Web of Science ®Google Scholar
• Farahani M, Bokharaei-Salim F, Ghane M, et al. Prevalence of occult hepatitis C virus infection in Iranian patients with lymphoproliferative disorders. J Med Virol. 2013;85:235–240.
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisaturo M, Guastafierro S, et al. Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy. Digestive Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2012;44:49–54.
   Google Scholar
• Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012;30:980–988.
   PubMed Web of Science ®Google Scholar
• Lundin J, Porwit-MacDonald A, Rossmann ED, et al. Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia. Leukemia. 2004;18:484–490.
   PubMed Web of Science ®Google Scholar
• Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and of atumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12:2031–2042.
   PubMed Web of Science ®Google Scholar
• Thompson PA, Burger JA. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opin Investig Drugs. 2018;27:31–42.
   PubMed Web of Science ®Google Scholar
• Ayed AO, Parikh SA. Management of patients with chronic lymphocytic leukemia at high risk of relapse on ibrutinib therapy. Leuk Lymphoma. 2017;1–10.
   PubMedGoogle Scholar
• Vladareanu AM, Cisleanu D, Dervesteanu M, et al. Myeloma cells with asurophilic granules–an unusual morphological variant – case presentation. J Med Life. 2008;1:74–86.
   PubMedGoogle Scholar
• Bagacean C, Tempescul A, Patiu M, et al. Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report. Ott. 2017;10:31–34.
   Google Scholar
• Awan FT, Byrd JC. New strategies in chronic lymphocytic leukemia: shifting treatment paradigms. Clin Cancer Res: Off J Am Assoc Cancer Res. 2014;20:5869–5874.
   PubMed Web of Science ®Google Scholar
• Collett L, Howard DR, Munir T, et al. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials. 2017;18:387.
   PubMed Web of Science ®Google Scholar
• Jain P, Keating MJ, Wierda WG, et al. Long-term follow-up of treatment with ibrutinib and rituximab in patients with high-risk chronic lymphocytic leukemia. Clin Cancer Res. 2017;23:2154–2158.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–211.
   PubMed Web of Science ®Google Scholar
• Waldron M, Winter A, Hill BT. Pharmacokinetic and pharmacodynamic considerations in the treatment of chronic lymphocytic leukemia: ibrutinib, idelalisib, and venetoclax. Clin Pharmacokinet. 2017;56:1255–1266.
   PubMed Web of Science ®Google Scholar
• Jones JA, Robak T, Brown JR, et al. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4:e114–e126.
   PubMed Web of Science ®Google Scholar
• Slinger E, Thijssen R, Kater AP, et al. Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition. Leukemia. 2017;31:2601–2607.
   PubMed Web of Science ®Google Scholar
• Kwok M, Rawstron AC, Varghese A, et al. Minimal residual disease is an independent predictor for 10-year survival in CLL. Blood. 2016;128:2770–2773.
   PubMed Web of Science ®Google Scholar
• Kovacs G, Robrecht S, Fink AM, et al. Minimal residual disease assessment improves prediction of outcome in patients with ChronicLymphocytic Leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group. J Clin Oncol. 2016;34:3758–3765.
   PubMed Web of Science ®Google Scholar
• Schwarzbich MA, McClanahan F, Gribben J. Allogeneic transplantation for chronic lymphocytic leukemia in the age of novel treatment strategies. Oncology. 2016;30:526–533, 540.
   PubMed Web of Science ®Google Scholar
• Kharfan-Dabaja MA, El-Asmar J, Awan FT, et al. Current state of hematopoietic cell transplantation in CLL as smart therapies emerge. Best Pract Res Clin Haematol. 2016;29:54–66.
   PubMed Web of Science ®Google Scholar
• Esteve J, Villamor N, Colomer D, et al. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status. Leukemia. 2001;15:445–451.
   PubMed Web of Science ®Google Scholar
• Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116:2438–2447.
   PubMed Web of Science ®Google Scholar
• Moreno C, Villamor N, Colomer D, et al. Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood. 2006;107:4563–4569.
   PubMed Web of Science ®Google Scholar
• Bottcher S, Ritgen M, Dreger P. Allogeneic stem cell transplantation for chronic lymphocytic leukemia: lessons to be learned from minimal residual disease studies. Blood Rev. 2011;25:91–96.
   PubMed Web of Science ®Google Scholar
• Ritgen M, Bottcher S, Stilgenbauer S, et al. Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial. Leukemia. 2008;22:1377–1386.
   PubMed Web of Science ®Google Scholar
• Ritgen M, Stilgenbauer S, von Neuhoff N, et al. Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood. 2004;104:2600–2602.
   PubMed Web of Science ®Google Scholar
• Aalbers AM, Aarts MJ, Krol AD, et al. The beneficial local and abscopal effect of splenic irradiation in frail patients with chronic lymphocytic leukaemia. Neth J Med. 2016;74:122–129.
   PubMed Web of Science ®Google Scholar
• Frinc I, Dima D, Chitic M, et al. Transthoracic ultrasonography for the follow-up of a chronic lymphocytic leukemia patient with chemotherapy-induced immunosuppression prior to allogeneic stem cell transplantation. A case report. Med Ultrasonogr. 2017;19:330–332.
   PubMed Web of Science ®Google Scholar
• Frinc I, Ilies P, Zaharie F, et al. Transthoracic ultrasonography for the immunocompromised patient. A pilot project that introduces transthoracic ultrasonography for the follow-up of hematological patients in Romania. Romanian J Internal Med = Revue Roumaine De Medecine Interne. 2017;55:103–116.
   PubMed Web of Science ®Google Scholar
• Porter DL, Hwang WT, Frey NV, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139.
   PubMed Web of Science ®Google Scholar
• Strati P, Keating MJ, O'Brien SM, et al. Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood. 2014;123:3727–3732.
   PubMed Web of Science ®Google Scholar
• Dimier N, Delmar P, Ward C, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate endpoint in CLL. Blood. 2018;131:955–962.
   PubMed Web of Science ®Google Scholar
• Sayala HA, Rawstron AC, Hillmen P. Minimal residual disease assessment in chronic lymphocytic leukaemia. Best Pract Res Clin Haematol. 2007;20:499–512.
   PubMed Web of Science ®Google Scholar
• Mattarucchi E, Spinelli O, Rambaldi A, et al. Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis. J Mol Diagn: JMD. 2009;11:482–487.
   PubMed Web of Science ®Google Scholar
• Moravcova J, Nadvornikova S, Sieglova Z, et al. Do transcriptionally silent BCR-ABL cells persist in CML patients in molecular remission after stem cell transplantation? Leukemia. 2001;15:997–999.
   PubMed Web of Science ®Google Scholar
• Sekiya Y, Xu Y, Muramatsu H, et al. Clinical utility of next-generation sequencing-based minimal residual disease in paediatric B-cell acute lymphoblastic leukaemia. Br J Haematol. 2017;176:248–257.
   PubMed Web of Science ®Google Scholar
• Ladetto M, Bruggemann M, Monitillo L, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia. 2014;28:1299–1307.
   PubMed Web of Science ®Google Scholar
• Innao V, Allegra A, Russo S, et al. Standardisation of minimal residual disease in multiple myeloma. Eur J Cancer Care (Engl). 2017;26. DOI: 10.1111/ecc.12732
   PubMed Web of Science ®Google Scholar
• Shin S, Hwang IS, Kim J, et al. Detection of immunoglobulin heavy chain gene clonality by next-generation sequencing for minimal residual disease monitoring in B-lymphoblastic leukemia. Ann Lab Med. 2017;37:331–335.
   PubMed Web of Science ®Google Scholar
• Kotrova M, van der Velden VHJ, van Dongen JJM, et al. Next-generation sequencing indicates false-positive MRD results and better predicts prognosis after SCT in patients with childhood ALL. Bone Marrow Transplant. 2017;52:962–968.
   PubMed Web of Science ®Google Scholar
• Gaipa G, Cazzaniga G, Valsecchi MG, et al. Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia. Haematologica. 2012;97:1582–1593.
   PubMed Web of Science ®Google Scholar
• Schrappe M. Minimal residual disease: optimal methods, timing, and clinical relevance for an individual patient. Hematol Am Soc Hematol Educ Program. 2012;2012:137–142.
   PubMedGoogle Scholar
• Hillmen P. Beyond detectable minimal residual disease in chronic lymphocytic leukemia. Semin Oncol. 2006;33:S23–S28.
   PubMed Web of Science ®Google Scholar
• Robertson LE, Huh YO, Butler JJ, et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood. 1992;80:29–36.
   PubMed Web of Science ®Google Scholar
• Vuillier F, Claisse JF, Vandenvelde C, et al. Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone-marrow remission using CD5-CD19 markers and PCR study of gene rearrangements. Leuk Lymphoma. 1992;7:195–204.
   PubMed Web of Science ®Google Scholar
• Lenormand B, Bizet M, Fruchart C, et al. Residual disease in B-cell chronic lymphocytic leukemia patients and prognostic value. Leukemia. 1994;8:1019–1026.
   PubMed Web of Science ®Google Scholar
• Cabezudo E, Matutes E, Ramrattan M, et al. Analysis of residual disease in chronic lymphocytic leukemia by flow cytometry. Leukemia. 1997;11:1909–1914.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956–964.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Kennedy B, Evans PA, et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood. 2001;98:29–35.
   PubMed Web of Science ®Google Scholar
• Stehlikova O, Chovancova J, Tichy B, et al. Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2014;36:165–171.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, Bottcher S, Letestu R, et al. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL. Leukemia. 2013;27:142–149.
   PubMed Web of Science ®Google Scholar
• Raponi S, Della Starza I, De Propris MS, et al. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR. Br J Haematol. 2014;166:360–368.
   PubMed Web of Science ®Google Scholar
• Rawstron AC, de Tute R, Jack AS, et al. Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia. 2006;20:2102–2110.
   PubMed Web of Science ®Google Scholar
• Sartor MM, Gottlieb DJ. A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2013;84:96–103.
   PubMedGoogle Scholar
• Farren TW, Giustiniani J, Fanous M, et al. Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia. Blood Cancer J. 2015;5:e273.
   PubMed Web of Science ®Google Scholar
• Dowling AK, Liptrot SD, O'Brien D, et al. Optimization and validation of an 8-color single-tube assay for the sensitive detection of minimal residual disease in b-cell chronic lymphocytic leukemia detected via flow cytometry. Lab Med. 2016;47:103–111.
   PubMed Web of Science ®Google Scholar
• Short NJ, Keating MJ, Wierda WG, et al. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia. Cancer. 2015;121:3869–3876.
   PubMed Web of Science ®Google Scholar
• Montillo M, Cafro AM, Tedeschi A, et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica. 2002;87:695–700.
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer. 2008;112:119–128.
   PubMed Web of Science ®Google Scholar
• Wendtner CM, Ritgen M, Schweighofer CD, et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission–experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia. 2004;18:1093–1101.
   PubMed Web of Science ®Google Scholar
• Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4578–4584.
   PubMed Web of Science ®Google Scholar
• Moreton P, Kennedy B, Lucas G, et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol. 2005;23:2971–2979.
   PubMed Web of Science ®Google Scholar
• Wierda WG. Minimal residual disease provides treatment focus for next chronic lymphocytic leukemia advances. J Clin Oncol. 2016;34:3722–3723.
   PubMed Web of Science ®Google Scholar
• Moreno C, Ritgen M, Rawstron A. Is MRD eradication a desirable goal in CLL? Best Pract Res Clin Haematol. 2010;23:97–107.
   PubMed Web of Science ®Google Scholar
• Caballero D, Garcia-Marco JA, Martino R, et al. Allogeneic transplant with reduced intensity conditioning regimens may overcome the poor prognosis of B-cell chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene and chromosomal abnormalities (11q- and 17p-). Clin Cancer Res: Off J Am Assoc Cancer Res. 2005;11:7757–7763.
   PubMed Web of Science ®Google Scholar
• Santacruz R, Villamor N, Aymerich M, et al. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. Haematologica. 2014;99:873–880.
   PubMed Web of Science ®Google Scholar
• van Dongen JJ, Langerak AW, Bruggemann M, et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia. 2003;17:2257–2317.
   PubMed Web of Science ®Google Scholar
• Logan AC, Gao H, Wang C, et al. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment. Proc Natl Acad Sci USA. 2011;108:21194–21199.
   PubMed Web of Science ®Google Scholar
• Logan AC, Zhang B, Narasimhan B, et al. Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia. 2013;27:1659–1665.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Pleasance ED, Stephens PJ, et al. Subclonal phylogenetic structures in cancer revealed by ultra-deep sequencing. Proc Natl Acad Sci USA. 2008;105:13081–13086.
   PubMed Web of Science ®Google Scholar
• Sarantopoulos S, Stevenson KE, Kim HT, et al. Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease. Blood. 2011;117:2275–2283.
   PubMed Web of Science ®Google Scholar
• Varghese AM, Rawstron AC, Hillmen P. Eradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment? Curr Hematol Malig Rep. 2010;5:35–44.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Coutre S, Hillmen P. Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime? Br J Haematol. 2007;136:379–392.
   PubMed Web of Science ®Google Scholar
• Evans PA, Pott C, Groenen PJ, et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia. 2007;21:207–214.
   PubMed Web of Science ®Google Scholar